Cytokinetics, Incorporated (CYTK) vs Protagonist Therapeutics, Inc. (PTGX)
- Cytokinetics, Incorporated CYTK 61.95 −3.08%
- Protagonist Therapeutics, Inc. PTGX 128.75 −5.71%
Cytokinetics, Incorporated and Protagonist Therapeutics, Inc. are both Biotechnology companies. Cytokinetics, Incorporated and Protagonist Therapeutics, Inc. are of similar size ($8.9B and $8.8B). Cytokinetics, Incorporated has negative trailing earnings, so its P/E is not meaningful; Protagonist Therapeutics, Inc. trades at 106×. Protagonist Therapeutics, Inc. grew revenue faster over the last twelve months: 34.8% against −21.1%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs −1,321.1%) and the higher return on invested capital (61.8% vs 0.00%). Across the 17 metrics below, Protagonist Therapeutics, Inc. leads on 13 and Cytokinetics, Incorporated on 4.
Valuation
Profitability
| Metric | CYTK | PTGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 87.97% | 100.00% | 65.16% |
| Operating margin | (1,046.12%) | 20.69% | 0.00% |
| Net margin | (1,321.12%) | 29.40% | 0.00% |
| Free cash flow margin | (858.16%) | 46.31% | 0.00% |
| Return on equity | 329.76% | 10.98% | (56.36%) |
| Return on assets | (56.76%) | 10.34% | (48.04%) |
| Return on invested capital | 0.00% | 61.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack